JP2024511973A5 - - Google Patents

Info

Publication number
JP2024511973A5
JP2024511973A5 JP2023556734A JP2023556734A JP2024511973A5 JP 2024511973 A5 JP2024511973 A5 JP 2024511973A5 JP 2023556734 A JP2023556734 A JP 2023556734A JP 2023556734 A JP2023556734 A JP 2023556734A JP 2024511973 A5 JP2024511973 A5 JP 2024511973A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutical composition
composition according
line
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020362 external-priority patent/WO2022197689A1/en
Publication of JP2024511973A publication Critical patent/JP2024511973A/ja
Publication of JP2024511973A5 publication Critical patent/JP2024511973A5/ja
Pending legal-status Critical Current

Links

JP2023556734A 2021-03-15 2022-03-15 Cns疾患および全身性疾患を治療するためのline-1阻害剤 Pending JP2024511973A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161050P 2021-03-15 2021-03-15
US63/161,050 2021-03-15
PCT/US2022/020362 WO2022197689A1 (en) 2021-03-15 2022-03-15 Line-1 inhibitors to treat cns and systemic diseases

Publications (2)

Publication Number Publication Date
JP2024511973A JP2024511973A (ja) 2024-03-18
JP2024511973A5 true JP2024511973A5 (https=) 2025-03-25

Family

ID=83321069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556734A Pending JP2024511973A (ja) 2021-03-15 2022-03-15 Cns疾患および全身性疾患を治療するためのline-1阻害剤

Country Status (15)

Country Link
US (1) US20240173346A1 (https=)
EP (1) EP4308237A4 (https=)
JP (1) JP2024511973A (https=)
KR (1) KR20230157430A (https=)
CN (1) CN117355312A (https=)
AU (1) AU2022237405A1 (https=)
BR (1) BR112023018714A2 (https=)
CA (1) CA3211369A1 (https=)
CL (1) CL2023002746A1 (https=)
DO (1) DOP2023000192A (https=)
IL (1) IL305869A (https=)
MA (1) MA62910A1 (https=)
MX (1) MX2023010657A (https=)
UA (1) UA130707C2 (https=)
WO (1) WO2022197689A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
WO2021102423A1 (en) 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US20250170158A1 (en) * 2022-02-22 2025-05-29 Rome Therapeutics, Inc. Methods of treating medical conditions using censavudine or a related compound
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
WO2023178128A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
CA3246792A1 (en) * 2022-03-30 2023-10-05 Transposon Therapeutics, Inc. NUCLEOSIDE LINE-1 INHIBITORS
WO2024129788A1 (en) * 2022-12-13 2024-06-20 Brown University Small molecule inhibitors of the line-1 endonuclease domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535045T3 (es) * 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
EP2965760A1 (en) * 2014-07-09 2016-01-13 Université de Montpellier Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases
CN105012305A (zh) * 2015-07-24 2015-11-04 福建广生堂药业股份有限公司 拉米夫定及其药用盐治疗老年性黄斑部病变的用途
RU2726210C2 (ru) * 2018-12-27 2020-07-09 Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" Комбинация противовирусных средств, набор и способ лечения на ее основе
EP3914604B1 (en) * 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑

Similar Documents

Publication Publication Date Title
JP2024511973A5 (https=)
JP2024540183A5 (https=)
JP2024133474A5 (https=)
RU2329050C2 (ru) Комбинация ингибиторов цитохром-р450-зависимых протеаз
JP2024029009A5 (https=)
JP2010532373A5 (https=)
JP2006503839A (ja) 真菌感染の処置のためのポサコナゾールの使用
JP2010532372A5 (https=)
JP2013082726A (ja) 鉄が病因に関与する肝臓疾患の処置
JP2022533968A5 (https=)
JP2017514911A5 (https=)
JP2023541766A5 (https=)
JP2024515829A5 (https=)
JP2023530264A5 (https=)
JP2021502392A5 (https=)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
CN111867582A (zh) 衣壳组装调节剂给药方案
JP2024520132A5 (https=)
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JPWO2023054732A5 (https=)
JP2022551691A5 (https=)
JP2023531675A5 (https=)
JP2019507786A5 (https=)
CA2516642A1 (en) Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors